Cantor Fitzgerald Reiterates Overweight Rating on Vaxcyte (PCVX), VAX-24 Study Patient Dosing Brings the Company Closer to Potential Commercialization
Tweet Send to a Friend
Cantor Fitzgerald analyst Louis Chen reiterated an Overweight rating and $55.00 price target on Vaxcyte (NASDAQ: PCVX), following announcement of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
